PT3326645T - Métodos para determinar as diferenças na atividade da integrina alfa-4 através da correlação de diferenças nos níveis de svcam e/ou smadcam - Google Patents

Métodos para determinar as diferenças na atividade da integrina alfa-4 através da correlação de diferenças nos níveis de svcam e/ou smadcam

Info

Publication number
PT3326645T
PT3326645T PT171928609T PT17192860T PT3326645T PT 3326645 T PT3326645 T PT 3326645T PT 171928609 T PT171928609 T PT 171928609T PT 17192860 T PT17192860 T PT 17192860T PT 3326645 T PT3326645 T PT 3326645T
Authority
PT
Portugal
Prior art keywords
differences
integrine
svcam
alfa
correlation
Prior art date
Application number
PT171928609T
Other languages
English (en)
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of PT3326645T publication Critical patent/PT3326645T/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PT171928609T 2010-10-25 2011-10-24 Métodos para determinar as diferenças na atividade da integrina alfa-4 através da correlação de diferenças nos níveis de svcam e/ou smadcam PT3326645T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40635810P 2010-10-25 2010-10-25
US40636510P 2010-10-25 2010-10-25

Publications (1)

Publication Number Publication Date
PT3326645T true PT3326645T (pt) 2020-06-23

Family

ID=46024768

Family Applications (2)

Application Number Title Priority Date Filing Date
PT171928609T PT3326645T (pt) 2010-10-25 2011-10-24 Métodos para determinar as diferenças na atividade da integrina alfa-4 através da correlação de diferenças nos níveis de svcam e/ou smadcam
PT201628443T PT3722808T (pt) 2010-10-25 2011-10-24 Métodos para determinar as diferenças na atividade da integrina alfa-4 através da correlação de diferenças nos níveis de svcam e/ou smadcam

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT201628443T PT3722808T (pt) 2010-10-25 2011-10-24 Métodos para determinar as diferenças na atividade da integrina alfa-4 através da correlação de diferenças nos níveis de svcam e/ou smadcam

Country Status (18)

Country Link
US (3) US20130337470A1 (pt)
EP (3) EP3722808B1 (pt)
JP (2) JP5847188B2 (pt)
AU (4) AU2011323820A1 (pt)
CA (1) CA2816016A1 (pt)
CY (1) CY1123060T1 (pt)
DK (2) DK3722808T3 (pt)
ES (3) ES2997080T3 (pt)
FI (1) FI3722808T3 (pt)
HR (2) HRP20241666T1 (pt)
HU (2) HUE050713T2 (pt)
LT (2) LT3326645T (pt)
PL (2) PL3326645T3 (pt)
PT (2) PT3326645T (pt)
RS (2) RS60565B1 (pt)
SI (2) SI3326645T1 (pt)
SM (2) SMT202000380T1 (pt)
WO (1) WO2012061074A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE050713T2 (hu) 2010-10-25 2020-12-28 Biogen Ma Inc Módszerek az ALFA-4 integrin aktivitás eltéréseinek meghatározásához, a sVCAM ÉS/VAGY sMAdCAM szintek egymáshoz viszonyításával
CA2969326A1 (en) 2014-12-02 2016-06-09 Nestec S.A. Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5338689A (en) 1987-08-24 1994-08-16 Stiftung Fur Diagnostische Forschung Method and card for detecting antigens and/or antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7238668B1 (en) 1989-09-01 2007-07-03 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with CS-1-peptides and fragments thereof
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5260210A (en) 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5224539A (en) 1991-06-14 1993-07-06 Coen Company, Inc. Cooling system for air heaters and the like
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
WO1994017828A2 (en) 1993-02-09 1994-08-18 Biogen, Inc. Treatment for insulin dependent diabetes
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB9406974D0 (en) 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
BE1008817A6 (fr) 1994-10-28 1996-08-06 Univ Bruxelles Procede d'obtention d'adn bicatenaire membranaire humain, produit obtenu par ce procede et trousse de diagnostic le contenant.
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
PL323130A1 (en) 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
US5965356A (en) 1997-01-31 1999-10-12 University Of Maryland, Baltimore Herpes simplex virus type specific seroassay
US6489300B1 (en) * 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE69940503D1 (de) * 1998-05-13 2009-04-16 Genentech Inc Diagnose und behandlung von hepatischen krankheiten
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6756378B2 (en) 1999-06-30 2004-06-29 Pharmacopeia Drug Discovery, Inc. VLA-4 inhibitor compounds
EP1244656A1 (en) 1999-12-28 2002-10-02 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
AU2001287000A1 (en) * 2000-09-01 2002-03-13 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
PL215263B1 (pl) 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
CA2514125A1 (en) 2003-01-24 2004-08-12 Elan Pharmaceuticals, Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
RU2358763C2 (ru) 2003-02-10 2009-06-20 Элан Фармасьютикалз, Инк. Композиции иммуноглобулина и способ их получения
EA009873B1 (ru) 2004-02-06 2008-04-28 Элан Фармасьютикалз, Инк. Способ ингибирования роста опухоли и/или метастатического прогрессирования
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
WO2005097162A2 (en) 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and their use
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
EP1871806A2 (en) 2005-03-08 2008-01-02 Pharmacia & Upjohn Company LLC ANTI-MAdCAM ANTIBODY COMPOSITIONS
EP3796003A1 (en) * 2005-04-04 2021-03-24 Biogen MA Inc. Methods for evaluating an immune response to a therapeutic agent
ES2752137T3 (es) 2006-02-28 2020-04-03 Biogen Ma Inc Métodos para tratar enfermedades inflamatorias y autoinmunes con natalizumab
WO2007103112A2 (en) 2006-03-03 2007-09-13 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
JP2011506322A (ja) 2007-12-07 2011-03-03 エラン ファーマシューティカルズ，インコーポレイテッド 液性腫瘍を治療するための方法および組成物
DK2279004T3 (en) * 2008-05-16 2015-02-02 Hoffmann La Roche USE OF biomarkers for assessment of treatment of gastrointestinal inflammatory disorders WITH beta7 integrin antagonists
WO2009141786A2 (en) 2008-05-21 2009-11-26 Piramal Life Sciences Limited Anti-inflammatory compounds
WO2010053316A2 (en) 2008-11-06 2010-05-14 Snu R&Db Foundation New use of sixth immunoglobulin-like domain of vcam-1
NZ577731A (en) * 2009-06-16 2010-08-27 Innate Therapeutics Ltd Compositions and methods for treatment of multiple sclerosis
CA2797974A1 (en) * 2010-04-30 2011-11-03 Elan Pharmaceuticals, Inc. Selective integrin inhibitors
HUE050713T2 (hu) 2010-10-25 2020-12-28 Biogen Ma Inc Módszerek az ALFA-4 integrin aktivitás eltéréseinek meghatározásához, a sVCAM ÉS/VAGY sMAdCAM szintek egymáshoz viszonyításával

Also Published As

Publication number Publication date
AU2011323820A1 (en) 2013-05-23
SI3326645T1 (sl) 2020-09-30
US20130337470A1 (en) 2013-12-19
JP2014500950A (ja) 2014-01-16
LT3326645T (lt) 2020-08-10
EP2632492A4 (en) 2014-04-02
US20160291035A1 (en) 2016-10-06
PT3722808T (pt) 2024-12-09
AU2021212059B2 (en) 2025-02-27
SMT202400498T1 (it) 2025-01-14
PL3722808T3 (pl) 2025-02-03
US11079393B2 (en) 2021-08-03
CA2816016A1 (en) 2012-05-10
RS60565B1 (sr) 2020-08-31
JP2015215363A (ja) 2015-12-03
EP3722808B1 (en) 2024-09-11
AU2017201658A1 (en) 2017-03-30
SI3722808T1 (sl) 2025-02-28
EP2632492B1 (en) 2017-10-04
EP3326645A1 (en) 2018-05-30
HUE069385T2 (hu) 2025-03-28
AU2021212059A1 (en) 2021-08-26
HRP20241666T1 (hr) 2025-02-14
AU2019204089A1 (en) 2019-07-04
EP3722808A1 (en) 2020-10-14
JP5847188B2 (ja) 2016-01-20
DK3326645T3 (da) 2020-06-15
DK3722808T3 (da) 2024-12-09
HRP20200920T1 (hr) 2020-10-30
HK1256157A1 (en) 2019-09-13
HUE050713T2 (hu) 2020-12-28
ES2800066T3 (es) 2020-12-23
AU2017201658B2 (en) 2019-03-21
ES2997080T3 (en) 2025-02-14
LT3722808T (lt) 2024-12-27
EP3326645B1 (en) 2020-03-18
RS66261B1 (sr) 2024-12-31
SMT202000380T1 (it) 2020-09-10
WO2012061074A1 (en) 2012-05-10
CY1123060T1 (el) 2021-10-29
PL3326645T3 (pl) 2020-09-21
US20220206012A1 (en) 2022-06-30
EP2632492A1 (en) 2013-09-04
FI3722808T3 (fi) 2024-12-10
ES2654820T3 (es) 2018-02-15

Similar Documents

Publication Publication Date Title
BR112014007789A2 (pt) sistemas e métodos para análise biológica
BR112013007499A2 (pt) piridazinonas - métodos de criação e usos
IL231996B (en) Virtual reality for movement disorder diagnosis and/or treatment
BR112013012969A2 (pt) índices de fatiga e usos para os mesmos
BR112013010272A2 (pt) métodos analíticos e arranjos para uso nos mesmos
EP2922861A4 (en) BIOMARKER COMPOSITIONS AND METHODS
PT2613774T (pt) Combinação de fenoxibenzamina e polimixina e para tratar infeções microbianas
BR112013010099A2 (pt) boronatos como inibidores de arginase
BR112013018877A2 (pt) composições farmacêuticas que compreendem anticorpos humanos para pcsk9
ES2685958T8 (es) Procedimiento para la detección temprana de trenes
BR112013014972A2 (pt) sistemas e métodos para uso de água com força iônica comutável
EP2568812A4 (en) NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
BR112013001710A2 (pt) aparelho para avaliar o estado da pele ou do cabelo
PT2751279T (pt) Métodos e composições para detetar o nível de atividade de exocitose lisossomal e métodos de utilização
PT3985979T (pt) Método e dispositivo para determinação de unidade de referência
BR112014012753A2 (pt) composição para pele e método de hidratação da pele
BR112014014213A2 (pt) agentes hemostáticos e método de utilização
EP2656275A4 (en) WHEEL SLIP SIMULATION SYSTEMS AND METHODS
BR112013012450A2 (pt) composições, métodos de detecção e kits
BR112013013656A2 (pt) marcador para determinação de sensitividade para agente anticâncer em combinação tripleto
BR112013015781A2 (pt) compostos e métodos para reparação da pele
BR112013005629A2 (pt) dispositivo e método para determinar condilçoes de esterilização
BR112013014915A2 (pt) composição curativa e métodos de tratamento
BR112013009577A2 (pt) composição de gel tópico e método
PT3326645T (pt) Métodos para determinar as diferenças na atividade da integrina alfa-4 através da correlação de diferenças nos níveis de svcam e/ou smadcam